[{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Mindset Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"MSP-1014","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McQuade Center for Strategic Research and Development \/ McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Center for Strategic Research and Development \/ McQuade Center for Strategic Research and Development"},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Sentinel Oncology","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"SOL784","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McQuade Center for Strategic Research and Development \/ Sentinel Oncology","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Center for Strategic Research and Development \/ Sentinel Oncology"},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Eikonizo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McQuade Center for Strategic Research and Development \/ Eikonizo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Center for Strategic Research and Development \/ Eikonizo Therapeutics"},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Rugen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McQuade Center for Strategic Research and Development \/ Rugen Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Center for Strategic Research and Development \/ Rugen Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by McQuade Center for Strategic Research and Development

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : MSRD has made a strategic investment to support the discovery and development of novel chemical entity assets of Mindset, a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          January 05, 2022

                          Lead Product(s) : MSP-1014

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Recipient : Mindset Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the terms of the agreement, MSRD and Sentinel will collaborate to support the Phase 1a and Phase 1b clinical trials for Sentinel’s investigational compound SOL784 with the opportunity to expand the collaboration after those studies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 03, 2021

                          Lead Product(s) : SOL784

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Sentinel Oncology

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the terms of the agreement, MSRD and Eikonizo will collaborate to advance Eikonizo’s HDAC6 inhibitors through preclinical and Phase 1b clinical studies respectively, with the opportunity to expand the collaboration after those studies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 09, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Eikonizo Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Activities will support the clinical development of Rugen’s potential first-in-class, orally administered drug candidate with initial clinical focus on treatment-resistant depression.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 30, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Rugen Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank